Gefallener Engel Stemcells fusioniert zu Microbot Medical Inc.
eröffnet am 13.09.17 12:49:35 von
neuester Beitrag 29.12.23 15:59:06 von
neuester Beitrag 29.12.23 15:59:06 von
Beiträge: 681
ID: 1.261.710
ID: 1.261.710
Aufrufe heute: 0
Gesamt: 31.393
Gesamt: 31.393
Aktive User: 0
ISIN: US59503A2042 · WKN: A2N5AS · Symbol: MBOT
0,8799
USD
-0,86 %
-0,0076 USD
Letzter Kurs 23.04.24 Nasdaq
Neuigkeiten
15.04.24 · globenewswire  |
05.02.24 · globenewswire |
30.01.24 · globenewswire |
18.01.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,3500 | +29,82 | |
| 1,5700 | +25,60 | |
| 0,6000 | +25,26 | |
| 1,8300 | +23,65 | |
| 0,7600 | +21,68 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7603 | -15,56 | |
| 0,6799 | -18,07 | |
| 2,8600 | -19,21 | |
| 27,00 | -49,30 | |
| 3,3900 | -53,94 |
Beitrag zu dieser Diskussion schreiben
Feedback
...und mal wieder genutzt:
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Microbot Medical Inc.
Fri, December 29, 2023 at 2:00 PM GMT+1
In this article:
MBOT
-14.63%
Watchlist
Watchlist
Recommendation Rating
Buy
Microbot Medical Inc.
Microbot Medical Inc.
BRAINTREE, Mass., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 1,685,682 shares of common stock, having exercise prices ranging from $2.075 to $3.19 per share, issued by Microbot in October 2022 and June 2023, at a reduced exercise price of $1.62 per share. The shares of common stock issuable upon exercise of the preferred investment options are registered pursuant to an effective resale registration statement on Form S-1 (File No. 333-273207). The closing of the offering is expected to occur on or about January 3, 2024, subject to satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
In consideration for the immediate exercise of the preferred investment options for cash, Microbot will issue new unregistered series E preferred investment options to purchase up to 1,685,682 shares of common stock. The new series E preferred investment options will have an exercise price of $1.50 per share, will be exercisable immediately upon issuance and have a term equal to five and one-half years from the date of issuance.
The gross proceeds to the Company from the exercise of the preferred investment options are expected to be approximately $2.73 million, prior to deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering for the continued development, commercialization and regulatory activities for the Company’s LIBERTY® Robotic System, expansion and development of additional applications derived from the Company’s existing IP portfolio, and for working capital and other general corporate purposes.
The new series E preferred investment options described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”), and, along with the shares of common stock issuable upon exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. Microbot has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new series E preferred investment options.
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Microbot Medical Inc.
Fri, December 29, 2023 at 2:00 PM GMT+1
In this article:
MBOT
-14.63%
Watchlist
Watchlist
Recommendation Rating
Buy
Microbot Medical Inc.
Microbot Medical Inc.
BRAINTREE, Mass., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 1,685,682 shares of common stock, having exercise prices ranging from $2.075 to $3.19 per share, issued by Microbot in October 2022 and June 2023, at a reduced exercise price of $1.62 per share. The shares of common stock issuable upon exercise of the preferred investment options are registered pursuant to an effective resale registration statement on Form S-1 (File No. 333-273207). The closing of the offering is expected to occur on or about January 3, 2024, subject to satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
In consideration for the immediate exercise of the preferred investment options for cash, Microbot will issue new unregistered series E preferred investment options to purchase up to 1,685,682 shares of common stock. The new series E preferred investment options will have an exercise price of $1.50 per share, will be exercisable immediately upon issuance and have a term equal to five and one-half years from the date of issuance.
The gross proceeds to the Company from the exercise of the preferred investment options are expected to be approximately $2.73 million, prior to deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering for the continued development, commercialization and regulatory activities for the Company’s LIBERTY® Robotic System, expansion and development of additional applications derived from the Company’s existing IP portfolio, and for working capital and other general corporate purposes.
The new series E preferred investment options described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”), and, along with the shares of common stock issuable upon exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. Microbot has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new series E preferred investment options.
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
Microbot Medical Inc.
Thu, December 28, 2023 at 1:30 PM GMT+1
In this article:
MBOT
-0.75%
Watchlist
Watchlist
Patternyahoo plus badge
Bullish
trade type L
Microbot Medical Inc.
Microbot Medical Inc.
The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical study
BRAINTREE, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model.
As previously announced on December 7, 2023, the study was conducted by three leading interventional radiologists that utilized the LIBERTY Endovascular Robotic Surgical System to perform a total of 96 robotic navigations. Target vessels with surrounding tissue were examined and evaluated microscopically after they were subjected to procedures using a range of commercially available intravascular catheterization devices controlled and manipulated via the LIBERTY Endovascular Robotic Surgical System.
“I am very pleased with the positive outcomes of the histopathology report and the completion of the GLP study,” said Juan Diaz Cartelle, Chief Medical Officer. “This gives us confidence to move forward to the next stage of human clinical studies.”
“Today’s announcement marks another important milestone for the Company, as we continue our transition from R&D and pre-clinical phase into the clinical, regulatory and pre-commercial phase,” commented Harel Gadot, CEO. “We expect to submit our IDE application to the FDA soon and commence our pivotal human clinical trial, completing our transition to a clinically stage company.”
Microbot Medical Inc.
Thu, December 28, 2023 at 1:30 PM GMT+1
In this article:
MBOT
-0.75%
Watchlist
Watchlist
Patternyahoo plus badge
Bullish
trade type L
Microbot Medical Inc.
Microbot Medical Inc.
The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical study
BRAINTREE, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model.
As previously announced on December 7, 2023, the study was conducted by three leading interventional radiologists that utilized the LIBERTY Endovascular Robotic Surgical System to perform a total of 96 robotic navigations. Target vessels with surrounding tissue were examined and evaluated microscopically after they were subjected to procedures using a range of commercially available intravascular catheterization devices controlled and manipulated via the LIBERTY Endovascular Robotic Surgical System.
“I am very pleased with the positive outcomes of the histopathology report and the completion of the GLP study,” said Juan Diaz Cartelle, Chief Medical Officer. “This gives us confidence to move forward to the next stage of human clinical studies.”
“Today’s announcement marks another important milestone for the Company, as we continue our transition from R&D and pre-clinical phase into the clinical, regulatory and pre-commercial phase,” commented Harel Gadot, CEO. “We expect to submit our IDE application to the FDA soon and commence our pivotal human clinical trial, completing our transition to a clinically stage company.”
2. offering
Kurz vor Börsenschluss gibt die Firma das 2. offering für 2,60 usd bekannt. Da haben einige Insider die Leiter auf beiden Seiten bespielt -.- Covern
Antwort auf Beitrag Nr.: 73.889.218 von Plomo_o_plata am 22.05.23 23:47:38danke für die Infos. Sieht legit aus. Habe nochmals eine Daytrading Position gekauft. Sollte das stimmen, dass die Short Position geschlossen wird und ein zweiten Spike auslöst dann nehme ich noch Gewinne mit. Wenn nicht, halte ich 1500 MBOT Aktien long. Damit kann ich auch gut leben.
Aber bei dem Hype, den MBOT gestern ausgelöst hat, wird heute nochmals 10-20 Millionen Aktien gehandelt...
Viel Erfolg allen.
Aber bei dem Hype, den MBOT gestern ausgelöst hat, wird heute nochmals 10-20 Millionen Aktien gehandelt...
Viel Erfolg allen.
Trading Spotlight
Es dieser Account der mit Insider wissen ordentlich abgeladen hat, ich traue denen zu das die den Short wie angekündigt beenden und es nochmal hochgeht, mal schauen 
von wegen! es wird weiterhin alles gekauft, schon wieder erholt von 2,8 auf 3,5 innerhalb von 15 Minuten!
Hier schreckt die Käufer nichts mehr ab!
Okay, hinterher ist man immer klüger aber trotzdem handele ich heute nicht mehr...
Sehr sehr positives Zeichen für die Longies. Alle die einen EK von über 5 oder gar 6$ haben sollten "rauskommen" falls das gewünscht ist.
Der Umsatz ist unglaublich!
Hier schreckt die Käufer nichts mehr ab!
Okay, hinterher ist man immer klüger aber trotzdem handele ich heute nicht mehr...
Sehr sehr positives Zeichen für die Longies. Alle die einen EK von über 5 oder gar 6$ haben sollten "rauskommen" falls das gewünscht ist.
Der Umsatz ist unglaublich!
was für eine Achterbahnfahrt, jetzt trading halt bei 3,09$. Abzusehen ist aber, dass es zu der Duftmarke 2,2$ geht.
Ich bin raus für heute.
Bei unter 2$ kauf ich ggf morgen pre-market
Ich bin raus für heute.
Bei unter 2$ kauf ich ggf morgen pre-market
direct offering zu 2,2$
ohje, okay. Der Kapitalmarkt ist einfach f*cked! heftiger Dämpfer, ähnlich wie bei IFRX
ohje, okay. Der Kapitalmarkt ist einfach f*cked! heftiger Dämpfer, ähnlich wie bei IFRX
Durchsuchen
